2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 3022

Characterizing a Novel Gene, Mosaic, and Its Role in Mediating a Multisystem Autoimmunity

T cell Biology and Targets in Autoimmune Disease Poster II

9:00AM-11:00AM: Abstract Number: 2549

Characterizing the RPTPσ Mediated Proteoglycan Switch As a Target for Rheumatoid Arthritis Therapy

Rheumatoid Arthritis - Animal Models Poster

9:00AM-11:00AM: Abstract Number: 3072

Childhood Takayasu Arteritis. a Single Center Experience

Vasculitis Poster III

9:00AM-11:00AM: Abstract Number: 2482

Choosing Subserologies More Wisely: Implementing Anti-Nuclear Antibody (ANA) Reflex Testing and Education to Reduce Unnecessary Costs in an Integrated Healthcare System

Quality Measures and Quality of Care Poster Session

9:00AM-11:00AM: Abstract Number: 2611

Circulating Monocyte Count Is Significantly Associated with Interstitial Pneumonia in Biologic-Naive Patients with Rheumatoid Arthritis: A Single-Center Prospective Cohort Study (Keio First-Bio Cohort Study)

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2183

Clinical and Epidemiological Correlates of the Adjusted Global Anti-Phospholipid Syndrome Score in a Large Cohort of Chinese APS Patients

Antiphospholipid Syndrome: Clinical

9:00AM-11:00AM: Abstract Number: 2452

Clinical and Functional Outcomes in Patients with Polyarticular Juvenile Idiopathic Arthritis Following Treatment with Adalimumab

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

9:00AM-11:00AM: Abstract Number: 2729

Clinical and Radiographic Outcome of Iguratimod for Rheumatoid Arthritis

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2667

Clinical Characteristics and Health Outcomes of RA Patients Not Adequately Controlled By Current Treatment

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2370

Clinical Characteristics of Anti-MDA5 (+) Dermatomyositis Patients in North America

Muscle Biology, Myositis and Myopathies Poster II: Autoantibodies and Treatments in Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 2256

Clinical Characteristics, Laboratory Findings and Nailfold Capillaroscopy Microscopy Patterns in a Monocentric Series of 123 Patients with Idiopathic Pernio

Epidemiology and Public Health Poster III (ACR): Gout and Non-Inflammatory Musculoskeletal Conditions

9:00AM-11:00AM: Abstract Number: 2438

Clinical Examination of the Temporomandibular Joint; A Eurotmjoint Initiative

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

9:00AM-11:00AM: Abstract Number: 3066

Clinical Features and Treatments of Takayasu Arteritis Complicated with Ulcerative Colitis

Vasculitis Poster III

9:00AM-11:00AM: Abstract Number: 2376

Clinical Features in Dermatomyositis Patients with Novel Autoantibody to Small Ubiquitin-like Modifier Activating Enzymes (Anti-SAE Antibody) and Relationship to Interstitial Lung Disease: A Systematic Review of 29 Cases

Muscle Biology, Myositis and Myopathies Poster II: Autoantibodies and Treatments in Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 2379

Clinical Follow-up Predictors of Disease Pattern Change in Anti Jo-1 Positive Antisynthetase Syndrome: Results from a Multicenter, International and Retrospective Study

Muscle Biology, Myositis and Myopathies Poster II: Autoantibodies and Treatments in Inflammatory Myopathies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].